Our proprietary platform technology Abiprot® can identify high-affinity antibody binding sites in any given protein with single amino acid resolution. It is based on using a tailored molecular reporter system and proteomics. The platform yields detailed sequence and structure information for epitope identification and development.
Abiprot® works well with both soluble and membrane bound proteins, and, in some instances, we can also control the pharmacology of our antibodies by careful selection of epitopes to yield either antagonistic or agonistic antibodies.
Trkulja C.L. et al; Rational Antibody design for Undruggable Targets using Kinetically Controlled Biomolecular Probes. Science Advances 16 Apr 2021; Vol. 7, no. 16, eabe6397
Trkulja C.L. et al; Probing Structure and Function of Ion Channels Using Limited Proteolysis and Microfluidics. J. Am. Chem. Soc. 2014; 136, 42, 14875–14882